NCT03951623View on ClinicalTrials.gov

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

October 30, 2021

Study Completion Date

July 31, 2022

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

HMPL-523

HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.

DRUG

Placebo

HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.

Trial Locations (1)

300000

Blood diseases hospital, Chinese academy of medical university, Tianjin

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT03951623 - The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | Biotech Hunter | Biotech Hunter